Single dose of magic mushroom psychedelic can cause anatomical brain changes, study finds
전체 오디오 미리듣기
0:00
0:00
#1
Single Dose of Psilocybin Linked to Lasting Anatomical Brain Changes, Researchers Report
研究人員報告：單劑量的賽洛西賓與持久的大腦解剖結構變化有關
#2
A groundbreaking study has revealed that a single 25-milligram dose of psilocybin may trigger measurable changes in brain anatomy.
一項突破性的研究顯示，單次 25 毫克的賽洛西賓劑量可能會引發大腦解剖結構上可測量的變化。
#3
Participants, all of whom were first-time users of the psychedelic compound, underwent specialised brain scans before and after ingestion.
參與者（皆為首次使用該致幻化合物的人員）在攝入前後接受了專門的腦部掃描。
#4
The research findings indicated that certain nerve tracts had become denser and more robust within just one month of taking the substance.
研究結果顯示，在服用該物質僅一個月內，某些神經束已變得更加密集且強韌。
#5
Scientists employed diffusion-based imaging to measure how water molecules travel along nerve bundles, thereby gauging structural integrity.
科學家採用擴散造影技術來測量水分子如何沿著神經束移動，從而評估結構的完整性。
#6
The observed neuroplasticity stood in stark contrast to the deterioration typically associated with ageing and dementia.
所觀察到的神經塑造性與通常與老化和失智症相關的退化現象形成了鮮明的對比。
#7
Were these preliminary findings to be confirmed by larger trials, they could fundamentally reshape our understanding of how psychedelics exert therapeutic effects.
倘若這些初步發現能被更大規模的試驗所證實，它們將從根本上重塑我們對於迷幻劑如何發揮治療功效的理解。
#8
Professor Robin Carhart-Harris, a neurologist at the University of California, San Francisco, emphasised the extraordinary nature of the results.
加州大學舊金山分校的神經學家羅賓·卡哈特-哈里斯教授強調了研究結果的非凡性質。
#9
He cautioned that the precise implications of the anatomical changes remain unclear, yet he acknowledged that participants reported deeper psychological insight and enhanced wellbeing.
他提醒道，解剖結構變化的確切影響尚不清楚，但他同時也承認，參與者報告了更深層的心理洞察力以及增進的幸福感。
#10
Not only did volunteers exhibit improved mental flexibility, but they also sustained these benefits for at least four weeks following the single dose.
志願者不僅展現出心理靈活性的提升，而且在服用單次劑量後的至少四週內，他們仍持續保有這些益處。
#11
The study arrives amid a surge of scientific interest in psychedelic-assisted therapies for mental health disorders.
這項研究是在科學界對迷幻劑輔助治療心理健康疾病的興趣激增之際發表的。
#12
Ongoing clinical trials are investigating whether psilocybin could offer relief for conditions ranging from treatment-resistant depression to chronic addiction.
目前的臨床試驗正在研究賽洛西賓是否能為從難治性憂鬱症到慢性成癮等病症提供緩解。
#13
Should subsequent research corroborate these findings, regulatory bodies may face mounting pressure to reconsider the legal status of such compounds.
若後續研究證實這些發現，監管機構可能會面臨重新考慮此類化合物法律地位的日益增長的壓力。